Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 25 Parkinson's papers of 1,349 | 0.57 |
| pathways Reactome | 4 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 7095
Sealed predictions
- ATG12 in dopamine neurons, braak+0.62 (p 0.078) → +0.48 (p 0.190)receipt 7102
Swarm cases
receipt 7102: ATG12 in dopamine neurons, braak
- power
- full sample +0.52 (p 0.026, n 18), 95% CI +0.07 to +0.80. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.49 (p 0.037, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.64 (p 0.0040, n 18). not the mix.
- skeptic
- leave-one-out range +0.46 to +0.67, sign flips 0; without severely affected donors +0.52 (p 0.026, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ATG12 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts